The present invention provides an electrolyte solution for a non-aqueous electrolyte battery capable of an exerting high average discharge voltage and an excellent low-temperature output characteristic at −30° C. or lower and an excellent cycle characteristic and an excellent storage characteristic at high temperatures of 50° C. or higher, as well as a non-aqueous electrolyte battery containing the same. The present electrolyte solution comprises anon-aqueous solvent, a solute, at least one silane compound represented by the following general formula (1) as a first compound, and a fluorine-containing compound represented by the following general formula (3), for example, as a second compound. ##STR00001##

The present invention provides an electrolyte solution for a non-aqueous electrolyte battery capable of an exerting high average discharge voltage and an excellent low-temperature output characteristic at −30° C. or lower and an excellent cycle characteristic and an excellent storage characteristic at high temperatures of 50° C. or higher, as well as a non-aqueous electrolyte battery containing the same. The present electrolyte solution comprises anon-aqueous solvent, a solute, at least one silane compound represented by the following general formula (1) as a first compound, and a fluorine-containing compound represented by the following general formula (3), for example, as a second compound. ##STR00001##

The invention provides mesotrione copper chelate form I and mesotrione copper chelate form II. A process for preparing mesotrione copper chelate form I and mesotrione copper chelate form II is also disclosed. Further, the present invention provides process for preparing mesotrione metal chelate polymorphs and agrochemical formulations comprising such polymorphs.

The invention provides mesotrione copper chelate form I and mesotrione copper chelate form II. A process for preparing mesotrione copper chelate form I and mesotrione copper chelate form II is also disclosed. Further, the present invention provides process for preparing mesotrione metal chelate polymorphs and agrochemical formulations comprising such polymorphs.

The present invention relates to a compound of formula I, or an isotopic form, stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing the compounds and their use in the treatment of diseases or disorders mediated by RORγ.

The present invention relates to a compound of formula I, or an isotopic form, stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing the compounds and their use in the treatment of diseases or disorders mediated by RORγ.

The present disclosure relates to reagents and method for performing trifluoromethylation, difluoromethylation or alkylation of aromatic or heteroaromatic rings in a redox-neutral manner without any catalyst which are enabled by light. In addition, there are methods for synthesizing the starting reagents used in the trifluoromethylation, difluoromethylation or alkylation reactions.

The present disclosure relates to reagents and method for performing trifluoromethylation, difluoromethylation or alkylation of aromatic or heteroaromatic rings in a redox-neutral manner without any catalyst which are enabled by light. In addition, there are methods for synthesizing the starting reagents used in the trifluoromethylation, difluoromethylation or alkylation reactions.

Disclosed herein are compounds and compositions for nematode treatment. In particular, disclosed are compounds of formula (I), a method of treating a plant or a growing media for a nematode with compounds of formula (II), compositions, and methods of use.

Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.